The head of the InnoRx tack is not exposed to the orbital socket, so it differs from a catheter. The head is covered over with tissue to block the pathway for infection and prevent irritation of the eye socket, similar to the implantable eye jewelry that is in fashion. Thus, a small, shallow incision is required to remove it.
In the QLTI message referenced from #msg-5168461, I stated that a drawback of Atrigel is that it can’t easily be removed (as the implant devices can) if there is a serious adverse reaction. Moreover, Atrigel appears to come up short compared to the implant devices in terms of duration of action. Comments? T.i.a.
Bausch & Lomb Licenses Novel Compounds From Cephalon for Ophthalmic Use
[As a player in ophthalmology, BOL has been embarrassingly MIA in the AMD arena other than as a purveyor of vitamins for eye health (which have been a big seller). BOL does, however, have an implant technology that could be married to one or more of the compounds that are brought forward under this license from CEPH. Or BOL could drop the implant idea and just develop the CEPH compounds per se. For a discussion of how BOL’s implant technology compares to implants from AGN, SRDX, and others, please see #msg-5182508.]
ROCHESTER, N.Y.--(BUSINESS WIRE)--Dec. 1, 2005--Bausch & Lomb (NYSE:BOL ) announced today that it has signed a definitive agreement for an exclusive worldwide license from Cephalon, Inc. of Frazer, Pa., to develop, market and sell ophthalmic products containing compounds that inhibit angiogenesis.
"Our licensing agreement with Cephalon is an example of how we at Bausch & Lomb are actively pursuing new compounds, therapies and technologies to treat diseases that rob people of their sense of sight," said Praveen Tyle, Ph.D., Bausch & Lomb Chief Scientific Officer and senior vice president - Global Research & Development. "We are interested in evaluating the therapeutic potential of small-molecule angiogenesis inhibitors for the treatment of a variety of blinding conditions that either cause or result from the abnormal growth of blood vessels within the eye. These diseases include the wet form of age-related macular degeneration, the No. 1 cause of blindness in the developed world, and diabetic macular edema.
"What is exciting is that preclinical data suggest these compounds may demonstrate a novel method of action by both stopping the abnormal growth of new blood vessels and by shrinking existing abnormal vessels. In addition, the small molecular size of these compounds makes them candidates for sustained release using our patented drug-delivery technology," Tyle said.
Jeffry L. Vaught, president of Research & Development at Cephalon, said, "Inhibition of angiogenesis is a common goal in both cancer research and in these common forms of retinal disease. There is evidence that vascular endothelial growth factor (VEGF) participates in retinal angiogenesis, and Cephalon's VEGF inhibitors have been shown in vivo to slow the growth of certain tumors. We are pleased to be associated with Bausch & Lomb, where experts in this field are pursuing potential new treatments for serious retinal disorders."
Under the terms of the agreement, Bausch & Lomb is responsible for preclinical and clinical development of compounds for use in ophthalmology. Bausch & Lomb will make a milestone payment to Cephalon upon regulatory acceptance of a New Drug Application and pay royalties based on product sales. Further details of the agreement are confidential.
Bausch & Lomb is the eye health company, dedicated to perfecting vision and enhancing life for consumers around the world. Its core businesses include soft and rigid gas permeable contact lenses and lens care products, and ophthalmic surgical and pharmaceutical products. The Bausch & Lomb name is one of the best known and most respected healthcare brands in the world. Founded in 1853, the Company is headquartered in Rochester, New York. Bausch & Lomb's 2004 revenues were $2.2 billion; it employs approximately 12,400 people worldwide and its products are available in more than 100 countries. More information about the Company can be found on the Bausch & Lomb Web site at www.bausch.com. <<
Market Data 
Markets 
AI
